NCT04332107View on ClinicalTrials.gov

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

PHASE3TerminatedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

March 16, 2021

Study Completion Date

March 30, 2021

Conditions
COVID-19SARS-CoV-2
Interventions
DRUG

Azithromycin

Participants will be shipped a single 1.2 g dose of oral azithromycin

DRUG

Placebos

Participants will be shipped a dose of matching placebo

Trial Locations (1)

94143

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Pfizer

INDUSTRY

collaborator

Stanford University

OTHER

lead

Thomas M. Lietman

OTHER